- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01364883
Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP
26. juli 2013 opdateret af: University of Oxford
A Phase I Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP
This is an open label phase I study, to assess the safety and immunogenicity of novel schedules for vaccination with the candidate malaria vaccines AdCh63 ME-TRAP and MVA ME-TRAP.
These vaccines have been evaluated previously in a number of clinical trials proved to be safe and capable of inducing protective cellular immune response following challenge with the parasite.
All volunteers recruited will be healthy adults.
They will be primed with AdCh63 ME-TRAP administered intramuscularly and boosted several times with AdCh63 ME-TRAP and MVA ME-TRAP according to various schedules.. Safety data will be collected for each of the seven regimens.
Secondary aims of this study will be to assess the immune responses generated by each of these regimes.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
39
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Oxford, Det Forenede Kongerige
- Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 50 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy adults aged 18 to 50 years
- Able and willing (in the Investigator's opinion) to comply with all study requirements
- Willing to allow the investigators to discuss their medical history with their General Practitioner
- For female volunteers, willingness to practice continuous effective contraception during the study
- Agreement to refrain from blood donation during the course of the study
- Written informed consent
Exclusion Criteria:
- Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
- Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
- Pregnancy, lactation, or intention to become pregnant during the study
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon History of clinically significant contact dermatitis
- Any history of anaphylaxis in relation to vaccination
- Any history of malaria Travel to a malaria endemic region during the study period or within the six months preceding enrolment in the study
- History of serious psychiatric condition that may affect participation in the study
- Any other serious chronic illness requiring hospital specialist supervision -Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
- Suspected or known injecting drug abuse in the five years preceding enrolment -Seropositive for hepatitis B surface antigen (HBsAg)
- Seropositive for hepatitis C virus (antibodies to HCV)
- Any relevant history of cancer (excludes basal cell carcinoma of the skin and cervical carcinoma in situ)
- Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
- Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of study data
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Group 1
AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
|
Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
|
Eksperimentel: Group 2
AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
|
Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
|
Eksperimentel: Group 3
AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
|
Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
|
Eksperimentel: Group 4
AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
|
Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
|
Eksperimentel: Group 5
AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
|
Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
|
Eksperimentel: Group 6
AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
|
Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
|
Eksperimentel: Group 7
AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
|
AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Vaccine Safety
Tidsramme: Participants will be followed for the duration of the study, an expected average of 21 months
|
To assess the safety of vaccination of healthy adults with AdCh63 ME-TRAP and MVA ME-TRAP according to vaccination schedules 1 to 7
|
Participants will be followed for the duration of the study, an expected average of 21 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Vaccine immunogenicity
Tidsramme: Participants will be followed for the duration of the study, an expected average of 21months
|
To assess the immunogenicity of vaccination of healthy adults with AdCh63 ME-TRAP and MVA ME-TRAP according to vaccination schedules 1 to 7
|
Participants will be followed for the duration of the study, an expected average of 21months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Adrian VS Hill, University of Oxford
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2011
Primær færdiggørelse (Faktiske)
1. juli 2013
Studieafslutning (Faktiske)
1. juli 2013
Datoer for studieregistrering
Først indsendt
31. maj 2011
Først indsendt, der opfyldte QC-kriterier
2. juni 2011
Først opslået (Skøn)
3. juni 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
29. juli 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. juli 2013
Sidst verificeret
1. juli 2013
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- VAC043
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts... og andre samarbejdspartnereRekrutteringPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLaos Demokratiske Folkerepublik
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanAfsluttetVivax malaria | Ukompliceret Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaAfsluttetPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis... og andre samarbejdspartnereAfsluttetMalaria | Vivax malaria | Falciparum malariaEtiopien, Bangladesh, Indonesien
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AfsluttetVivax malaria | Falciparum malariaIndonesien
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology og andre samarbejdspartnereAfsluttet
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet TPO og andre samarbejdspartnereAfsluttetMalaria | Vivax malaria | Falciparum malariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AfsluttetVivax malaria | Falciparum malariaIndonesien
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationAfsluttetMalaria | Vivax malaria | Falciparum malaria | Malaria Genopblomstring
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute for Advanced Medical Research and Training, University of Ibadan, IbadanAfsluttetPlasmodium Falciparum Malaria | Ukompliceret malaria | Malaria feberNigeria
Kliniske forsøg med Vaccination Schedule One
-
University of EdinburghNHS LothianAfsluttetBakterielle luftvejsinfektionerDet Forenede Kongerige
-
Nourhan M.AlyAfsluttetKlasse II CariesEgypten
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...RekrutteringFodsygdomme | Komplekse regionale smertesyndromer | Smerter, led | Ankel sygdomItalien
-
Biotronik SE & Co. KGAfsluttetVentrikulær takykardi, monomorfØstrig, Finland, Tyskland, Israel
-
ASST Fatebenefratelli SaccoALK-Abelló A/SAfsluttet
-
Charles University, Czech RepublicIkke rekrutterer endnuTilbagevenden | Cervikal Intraepitelial Neoplasi Grad 2/3Tjekkiet
-
Central Jutland Regional HospitalAfsluttetMedicinske patienterDanmark
-
Virginia Polytechnic Institute and State UniversityNational Institute of Mental Health (NIMH)AfsluttetAngstlidelser | Specifik fobiForenede Stater
-
Radboud University Medical CenterAfsluttetProstatiske neoplasmer | Immunterapi | Vacciner | Dendritiske cellerHolland